Compare
Vaxart, Inc. vs Iovance Biotherapeutics, Inc. vs Vericel Corp vs Adaptive Biotechnologies Corp
| Latest fiscal year | Vaxart, Inc. VXRT | Iovance Biotherapeutics, Inc. IOVA | Vericel Corp VCEL | Adaptive Biotechnologies Corp ADPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $237.26M | $263.50M | $276.26M | $276.98M |
| Revenue growth (YoY) | +726.7% | +60.6% | +16.5% | +54.8% |
| Gross margin | n/a | 34.3% (computed) | 74.4% (computed) | 74.2% (computed) |
| Operating margin | 7.6% | -153.1% | 4.0% | -20.6% |
| Net margin | 6.9% | -148.4% | 6.0% | -21.5% |
| Net income | $16.33M | -$390.98M | $16.52M | -$59.50M |
| EPS (Diluted) | $0.07 | -$1.09 | $0.32 | -$0.39 |
| Operating cash flow | $7.71M | -$302.41M | $51.91M | -$45.99M |
| Free cash flow | $7.57M | -$336.24M | $24.75M | -$48.95M |
| Cash & equivalents | n/a | $163.08M | $100.09M | $70.50M |
| Total assets | $186.08M | $913.17M | $487.97M | $512.74M |
| Total liabilities | $98.28M | $214.59M | $133.33M | $287.74M |
| Shareholders' equity | $87.80M | $698.58M | $354.64M | $218.79M |
| Return on year-end equity | 18.6% | -56.0% | 4.7% | -27.2% |
| Shares outstanding | 240.49M | 411.94M | 50.62M | 153.78M |
Revenue, most recent five fiscal years
| Fiscal year | Vaxart, Inc. | Iovance Biotherapeutics, Inc. | Vericel Corp | Adaptive Biotechnologies Corp |
|---|---|---|---|---|
| Latest | $237.26M Ended 2025-12-31 | $263.50M Ended 2025-12-31 | $276.26M Ended 2025-12-31 | $276.98M Ended 2025-12-31 |
| 1 year earlier | $28.70M Ended 2024-12-31 | $164.07M Ended 2024-12-31 | $237.22M Ended 2024-12-31 | $178.96M Ended 2024-12-31 |
| 2 years earlier | $7.38M Ended 2023-12-31 | $1.19M Ended 2023-12-31 | $197.52M Ended 2023-12-31 | $170.28M Ended 2023-12-31 |
| 3 years earlier | $107.0K Ended 2022-12-31 | n/a | $163.70M Ended 2022-12-31 | $185.31M Ended 2022-12-31 |
| 4 years earlier | $892.0K Ended 2021-12-31 | n/a | $153.07M Ended 2021-12-31 | $154.34M Ended 2021-12-31 |